SYFOVRE ™ (pegcetacoplan injection) FDA Approval

Conference Call

February 17, 2023

SYFOVRE™ (pegcetacoplan injection)

Apellis Participants

CEDRIC FRANCOIS, M.D., Ph.D.
Co-Founder & Chief Executive Officer

CAROLINE BAUMAL, M.D.
Chief Medical Officer

ADAM TOWNSEND
Chief Commercial Officer

TIM SULLIVAN
Chief Financial Officer

SYFOVRE™
(pegcetacoplan injection)

Forward Looking Statements

Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding timing of anticipated regulatory submissions or decisions. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether intravitreal pegcetacoplan will receive approval from foreign regulatory agencies for GA when expected or at all; and other factors discussed in the "Risk Factors" section of Apellis' Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2022 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

SYFOVRE is approved in the United States!

The **first and only** FDA approved treatment for geographic atrophy secondary to age-related macular degeneration

SYFOVRE™
(pegcetacoplan injection)

SYFOVRE is the only treatment available for GA

1. Increasing effects over time
2. Flexible dosing options (once every 25-60 days)
3. Indicated for all patients with GA, with or without subfoveal involvement
4. Well-demonstrated safety profile in ~12,000 injections over 24 months

Label includes positive 24-month efficacy and safety data

SYFOVRE™ (pegcetacoplan injection)

SYFOVRE provides comprehensive control of the complement cascade



Source: Merle NS, et al. Cell Research. 2010; 20:34-50.

SYFOVRE™ (pegcetacoplan injection)

we sincerely thank you…

GA patients, and their families and caregivers

healthcare professionals and our investigators

investors

team Apellis

…for your tireless dedication and unwavering commitment

SYFOVRE™ (pegcetacoplan injection)

SYFOVRE is now approved for GA patients in the US



>1M

Patients in the U.S.[1]

NORMAL VISION



VISION WITH ADVANCED GA



2/3 of GA patients become ineligible to drive within 2 years of diagnosis[2]

1 Boyer DS et al., Retina 2017
2 Chakravarthy et al. Ophthalmology 2018; 125(6):842-849

SYFOVRE™ (pegcetacoplan injection)

Treatment with every-other-month and monthly SYFOVRE resulted in a reduction of GA lesion growth across both studies

REDUCTION IN LESION GROWTH RATE WITH SYFOVRE VS SHAM POOLED[1]*†

OAKS



DERBY



*Based on a mixed effects model for repeated measures assuming a piecewise linear trend in time with knots at Month 6, Month 12, and Month 18.[1]
Slope for baseline to Month 24 is an average of slope of baseline to Month 6, Month 6 to Month 12, Month 12 to Month 18, and Month 18 to Month 24.[1]
†SHAM EOM and SHAM Monthly were pooled for analysis.[2]
SE=standard error; CI=confidence interval.

1. SYFOVRE (pegcetacoplan injection) [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc; 2023. 2. Data on file, Apellis Pharmaceuticals, Inc.

SYFOVRE™ (pegcetacoplan injection)

SYFOVRE demonstrated increased effects over 24 months

OAKS



DERBY



Percent reduction vs. Sham for Month 0 to Month 24 was estimated from a piecewise linear slope model with 6-months segments.

Percent reduction vs. sham for Month 0 to Month 24 was estimated from a piecewise linear slope model with 6-month segments.

SYFOVRE™ (pegcetacoplan injection)

SYFOVRE showed a well-demonstrated safety profile following nearly 12,000 injections

Most common adverse events:

- Ocular discomfort
- Neovascular age related macular degeneration
- Vitreous floaters
- Conjunctival hemorrhage

Rates of endophthalmitis and intraocular inflammation generally in line with those reported in studies of other intravitreal therapies

Rates of ION were higher in monthly compared to every-other-month and sham

No events of occlusive or non-occlusive vasculitis or retinitis were observed

SYFOVRE™ (pegcetacoplan injection)

U.S. launch is the first step towards bringing SYFOVRE to GA patients worldwide

- Marketing authorization application (MAA) validated and under review with EMA
- European Commission decision expected early 2024
- Submitted marketing application to Health Canada
- Submissions to Switzerland, Australia, U.K. expected in Q1

1 Boyer DS et al., Retina 2017

SYFOVRE™ (pegcetacoplan injection)

Best-in-class team with extensive retina experience ready to launch

~100 field-based employees calling on

~2,600 retina specialists and injecting ophthalmologists

Initial priority patients



Significant vision loss in one eye and foveal encroachment in other eye

wetAMD in one eye and GA in other eye

Bilateral GA

wetAMD and GA in the same eye

SYFOVRE™ (pegcetacoplan injection)

Strong value proposition for physicians and patients

- Vial price of $2,190, reflecting SYFOVRE clinical profile and recently approved anti-VEGFs
- >90% of patients will be covered by Medicare
- Permanent J-Code expected around October 1, 2023

SYFOVRE™ (pegcetacoplan injection)

We are committed to helping patients obtain access

ApellisAssist

- Inclusive insurance support
- Financial assistance for eligible patients
- Disease education
- Ongoing product support

SYFOVRE™ (pegcetacoplan injection)

SYFOVRE is approved in the United States!

The **first and only** FDA approved treatment for geographic atrophy secondary to age-related macular degeneration

SYFOVRE™
(pegcetacoplan injection)

Thank you

SYFOVRE™
(pegcetacoplan injection)